Long Non-coding RNA INE1 Induced Autophagy Promotes Sensitivity of Prostate Cancer Cells to Cisplatin
-
Published:2022-11-29
Issue:
Volume:
Page:1-12
-
ISSN:2617-7773
-
Container-title:annals of urologic oncology
-
language:en
-
Short-container-title:ann urol oncol
Author:
Chu Hezhen1, Li Kongdong2, Gu Jie2, Xie Wenchao3, Xie Yimin3, Ma Jun1
Affiliation:
1. Department of Urology, Yixing Traditional Chinese Medicine Hospital, Yixing, Jiangsu, China. 2. School of Life Sciences, Jiangsu University, Zhenjiang, Jiangsu, China. 3. Department of Urology, Affiliated Hospital of Jiangsu University-Yixing Hospital, Yixing, Jiangsu, China.
Abstract
Prostate cancer is most prevalent malignancy of males in the world. In recent years, long non-coding RNAs (lncRNAs) were identified, and their functions are associated with prostate cancer initiation and progression. However, their molecular mechanisms still need to be elucidated before the clinical utility. In the present study, we identified the correlation of lncRNA inactivation escape 1 (INE1) with the characterization in prostate cancer patients, and detected the roles of INE1 in cell autophagy and apoptosis in prostate cancer cells. Our results showed that the lncRNA INE1 expression highly correlate with patients’ survival times, tumor stage, biochemical recurrence, disease recurrence and Gleason pattern. High expression of INE1 was detected in prostate cancer cells, and knockdown INE1 by siRNA resulted in significant inhibition of cell viability. In addition, silencing INE1 induced early autophagy and pro-apoptosis, which augments cisplatin (CDDP)-induced cell apoptosis. Moreover, INE1 played an anti-apoptotic role by targeting the serine/arginine-rich splicing factor 2 (SRSF2).
Publisher
Asian Medical Press Limited
Subject
General Earth and Planetary Sciences,General Environmental Science
Reference47 articles.
1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2020. CA Cancer J Clin 2020, 70: 7-30. 2. Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, DiTommaso D, Karnofski K, Gulati R, Penson DF, Feuer E: Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control 2008, 19: 175-181. 3. Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, de Carvalho TM, Hugosson J, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Lujan M, Villers A, Feuer EJ, de Koning HJ, Mariotto AB, Etzioni R: Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. Ann Intern Med 2017, 167: 449-455. 4. Negoita S, Feuer EJ, Mariotto A, Cronin KA, Petkov VI, Hussey SK, Benard V, Henley SJ, Anderson RN, Fedewa S, Sherman RL, Kohler BA, Dearmon BJ, Lake AJ, Ma J, Richardson LC, Jemal A, Penberthy L: Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics. Cancer 2018, 124: 2801-2814. 5. Giordano TJ: The cancer genome atlas research network: a sight to behold. Endocr Pathol 2014, 25: 362-365.
|
|